---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-25-000046"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:12:12.676533+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SENTI-202 Phase 1 shows 5/7 ORR in R/R AML; RP2D set; cash $33.8M at Q1 2025

## Summary
- 5 of 7 evaluable R/R AML patients achieved ORR (3 CR, 1 CRh, 1 MLFS); all cCR patients MRD-negative.
- No dose-limiting toxicities; preliminary RP2D set at 1.5x10^9 CAR NK cells Days 0,7,14 per 28-day cycle.
- Longest ongoing response >8 months; 3 patients received bone marrow transplant after SENTI-202.
- Q1 2025 preliminary: cash $33.8M, net loss $14.1M ($1.41/share); R&D $9.3M, G&A $7.1M.
- SENTI-301A/SN301A HCC trial enrollment stopped due to dose-limiting toxicities; evaluating next steps.

## SEC filing metadata
- accession: 0001854270-25-000046
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/0001854270-25-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/snti-20250428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-25-000046
- JSON: https://secwatch.observer/filing/0001854270-25-000046.json
- Plain text: https://secwatch.observer/filing/0001854270-25-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.